Dolutegravir
Tivicay, Tivicay PD
NADAC/unit
$77.6627
No Shortage
Tier 1: 35.9%
TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.
vs. brand Tivicay: Generic saves up to -677% per unit
Market Intelligence
2024-06-12 Class III Recall: GlaxoSmithKline LLC
Generic Manufacturers
VIIV HEALTHCARE CO
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.